

<div style="display: flex; justify-content: space-between;"><div>P24014.P01</div><div style="text-align: center;">UTILITY PATENT APPLICATION TRANSMITTAL</div></div> <p style="font-size: small;">(Only for new nonprovisional applications under 37 CFR 1.53(b))</p>	Attorney Docket No. P24014	Total Pages <div style="border: 1px solid black; height: 20px; width: 100%;"></div>	
	Inventor(s) or Application Identifier Seong Hwan CHO, Yong Sik YOUN, Yun Taek JUNG, Choong Sil PARK, Hyuk Koo LEE, Kwang Hyeg LEE, Eun Ju JEONG, Young Hoon KIM, Hae Tak JIN, Jun Hee CHEON, Sung Hak LEE, Sung Hak JUNG, Dong Kwon LIM, Kyu Jeong YEON, Yun Cheul KIM, Kyung Mi PARK and Hyun Suk KANG		
	Title: ORGANIC ACID SALT OF AMLODIPINE		
<div style="display: flex; justify-content: space-between;"><div>ADDRESS TO:</div><div>Commissioner for Patents Mail Stop Patent Application PO Box 1450 Alexandria, VA 22313-1450</div></div>			
APPLICATION ELEMENTS		ACCOMPANYING APPLICATION PARTS	
<div>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</div> <div>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. a. <input type="checkbox"/> Small Entity Statement(s)</div> <div>3. <input checked="" type="checkbox"/> Specification (preferred arrangement set forth below) [Total Pages <u>18</u>] - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure</div> <div>4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <u> </u>]</div> <div>5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <u>10</u>] a. <input checked="" type="checkbox"/> Newly executed (original or copy) <input type="checkbox"/> Unexecuted b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20 completed) [Note Box 6 below] i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</div> <div>6. <input type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</div> <div>7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</div> <div>8. <input type="checkbox"/> CD-Rom or CD-R in duplicate, large table or Computer Program (Appendix)</div>		<div>9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies</div> <div>10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</div> <div>11. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney</div> <div>12. <input type="checkbox"/> English Translation Document (if applicable)</div> <div>13. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</div> <div>14. <input checked="" type="checkbox"/> Preliminary Amendment</div> <div>15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</div> <div>16. <input type="checkbox"/> Figure of Drawing to be published</div> <div>17. <input checked="" type="checkbox"/> Foreign priority claimed a. <input checked="" type="checkbox"/> Claim of Priority b. <input type="checkbox"/> Certified Copy of Priority Document(s)</div> <div>18. <input checked="" type="checkbox"/> Assignee: <u>CJ Corporation of Seoul, Republic of Korea</u></div> <div>19. <input checked="" type="checkbox"/> Other: <u>Cover Letter Regarding Executed Application</u> _____ _____ _____ _____</div>	
<div>20. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. <u> </u> / <u> </u>, filed <u> </u>. Prior application information: Examiner: <u> </u> Group Art Unit: <u> </u></div>			
<div>21. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <u> </u> continuation-in-part, <u> </u> continuation, <u> </u> divisional, of Application No. <u> </u> / <u> </u>, filed <u> </u>.</div>			

17354 U.S. PTO
10/628210
07/29/03

Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

7/29/03
Date


Signature Reg 16
33,329

Bruce H. Bernstein, Reg. No. 29,027
Typed or Printed Name

P24014.P02



FEE TRANSMITTAL

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Herewith
First Named Inventor	Seong Hwan CHO et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	P24014

TOTAL AMOUNT OF PAYMENT (\$750.00)

METHOD OF PAYMENT (check one)

1. ☒ The U.S. Patent and Trademark Office is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 19-0089

Deposit Account Name GREENBLUM & BERNSTEIN, P.L.C.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3))
- ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)
- ☐ Applicant Claims Small Entity Status See 37 CFR 1.27.

2. ☒ Payment Enclosed:

☒ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION (fees effective 01/01/03)

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	750.00
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$750.00)

2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
10	0	18	0
2	0	84	0
Multiple Dependent Claims	0	280	0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim
1204	84	2204	42	Reissue independent claims over original patent
1205	18	2205	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$0.00)

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR	
				Prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for response within 1st month	
1252	410	2252	205	Extension for response within 2nd month	
1253	930	2253	465	Extension for response within 3rd month	
1254	1,450	2254	725	Extension for response within 4th month	
1255	1,970	2255	985	Extension for response within 5th month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive unavoidably abandoned application	
1453	1,300	2453	650	Petition to revive unintentionally abandoned application	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of IDS	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

Other fee (specify) _____

SUBTOTAL (3) (\$0.00)

*Reduced by Basic Filing Fee paid

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name Bruce H. Bernstein

Reg. Number

29,027

Signature

Date

7/29/03

Deposit Account User ID

P24014.A02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Seong Hwan CHO et al.

Serial No : Not Yet Assigned

Filed : Concurrently Herewith

For : ORGANIC ACID SALT OF AMLODIPINE

COVER LETTER REGARDING EXECUTED APPLICATION

Commissioner for Patents
Alexandria, VA 22313-1450

Sir:


The undersigned points out that the executed application being filed herewith includes an executed declaration which includes an obvious error in the filing date of priority Application No. 10-**2002**-0044857. The filing date should be ---30 July **2002**--- instead of "30 July 2002".

Applicants respectfully submit that the present application is properly executed and should be considered as filed in executed form. However, if the U.S. Patent and Trademark Office determines that the present application is not properly executed, Applicants respectfully request that the present application be treated as an unexecuted application under 37 C.F.R. 1.53(f).

P24014.A02

Should there be any questions regarding this paper, please contact the undersigned at the below listed number.

Respectfully submitted,
Seong Hwan CHO et al.


Bruce H. Bernstein
Reg. No. 29,027

Reg No 33,329

July 29, 2003
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191